{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Langer C"],"funding":["NCI NIH HHS"],"pagination":["5371-9"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC2396728"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["111(11)"],"pubmed_abstract":["BAALC expression is considered an independent prognostic factor in cytogenetically normal acute myeloid leukemia (CN-AML), but has yet to be investigated together with multiple other established prognostic molecular markers in CN-AML. We analyzed BAALC expression in 172 primary CN-AML patients younger than 60 years of age, treated similarly on CALGB protocols. High BAALC expression was associated with FLT3-ITD (P = .04), wild-type NPM1 (P < .001), mutated CEBPA (P = .003), MLL-PTD (P = .009), absent FLT3-TKD (P = .005), and high ERG expression (P = .05). In multivariable analysis, high BAALC expression independently predicted lower complete remission rates (P = .04) when adjusting for ERG expression and age, and shorter survival (P = .04) when adjusting for FLT3-ITD, NPM1, CEBPA, and white blood cell count. A gene-expression signature of 312 probe sets differentiating high from low BAALC expressers was identified. High BAALC expression was associated with overexpression of genes involved in drug resistance (MDR1) and stem cell markers (CD133, CD34, KIT). Global microRNA-expression analysis did not reveal significant differences between BAALC expression groups. However, an analysis of microRNAs that putatively target BAALC revealed a potentially interesting inverse association between expression of miR-148a and BAALC. We conclude that high BAALC expression is an independent adverse prognostic factor and is associated with a specific gene-expression profile."],"journal":["Blood"],"pubmed_title":["High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study."],"pmcid":["PMC2396728"],"funding_grant_id":["CA098933","CA089341","CA096887","CA016058","CA101140","U24 CA114725","CA114725","CA077658","R01 CA089341","K01 CA096887","U10 CA077658","P30 CA016058","U10 CA101140","R01 CA098933"],"pubmed_authors":["Minka D","Muss HB","Meloni-Ehrig A","Crawford J","Tharapel SA","Qumsiyeh MB","Beauregard LJ","Perry MC","Baldus CD","Heerema NA","Larson RA","Paschka P","Clark JW","Liu MC","Ellerton J","Stein CK","Green MR","Walsh WW","Clamon GH","Pai GS","Richkind KE","de la Chapelle A","Cancer and Leukemia Group B (CALGB)","Liu CG","Dell'Aquila ML","Kolitz JE","Budman DR","Peterson BA","Segal HM","Nattam S","Ross ME","Ernstoff MS","Silverman LR","Flejter WL","Levine EG","Winer EP","Ruppert AS","Shadduck RK","Pacheco EI","Bader PI","Bernstein R","Huang TH","Le Beau MM","Leonard J","Rai KR","Langer C","Morrison VA","Fleming G","Pettenati MJ","Morton CC","Peace DJ","Radmacher MD","Whitman SP","Tantravahi R","Roulston D","Mohandas TK","Koduru PR","Jaswaney V","Watson MS","Allen EF","Shea T","Reid T","Mrozek K","Mitchell MJ","Tang M","Vukosavljevic T","Bloomfield CD","McCorquodale MM","Powell BL","Bartlett NL","Marcucci G","Patil SR","Parker BA","Mathew S","Miron P","Garcia-Heras J","Borgaonkar DS","Graziano SL","Theil KS","Ryan CJ","Roberts JD","Najfeld V","Block AW","Jackson-Cook C","Carroll AJ","Atkins LL","Grubbs SS","Sikov W","Hirsch BA","Dal Cin P","Rao KW","Hurd DD","Diggans GR","Meck JM"],"additional_accession":[]},"is_claimable":false,"name":"High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study.","description":"BAALC expression is considered an independent prognostic factor in cytogenetically normal acute myeloid leukemia (CN-AML), but has yet to be investigated together with multiple other established prognostic molecular markers in CN-AML. We analyzed BAALC expression in 172 primary CN-AML patients younger than 60 years of age, treated similarly on CALGB protocols. High BAALC expression was associated with FLT3-ITD (P = .04), wild-type NPM1 (P < .001), mutated CEBPA (P = .003), MLL-PTD (P = .009), absent FLT3-TKD (P = .005), and high ERG expression (P = .05). In multivariable analysis, high BAALC expression independently predicted lower complete remission rates (P = .04) when adjusting for ERG expression and age, and shorter survival (P = .04) when adjusting for FLT3-ITD, NPM1, CEBPA, and white blood cell count. A gene-expression signature of 312 probe sets differentiating high from low BAALC expressers was identified. High BAALC expression was associated with overexpression of genes involved in drug resistance (MDR1) and stem cell markers (CD133, CD34, KIT). Global microRNA-expression analysis did not reveal significant differences between BAALC expression groups. However, an analysis of microRNAs that putatively target BAALC revealed a potentially interesting inverse association between expression of miR-148a and BAALC. We conclude that high BAALC expression is an independent adverse prognostic factor and is associated with a specific gene-expression profile.","dates":{"release":"2008-01-01T00:00:00Z","publication":"2008 Jun","modification":"2026-03-27T17:23:42.053Z","creation":"2025-08-30T03:09:58.233Z"},"accession":"S-EPMC2396728","cross_references":{"pubmed":["18378853"],"doi":["10.1182/blood-2007-11-124958"]}}